Bioblast Pharma’s Experimental Muscle Wasting Drug Offers Hope

by Shirley Johanna on  October 28, 2015 at 10:23 AM Drug News
RSS Email Print This Page Comment
Font : A-A+

BioBlast Pharma announced promising results from a Phase 2 clinical study of its lead experimental drug to treat patients with rare muscle wasting disorder.
Bioblast Pharma’s Experimental Muscle Wasting Drug Offers Hope
Bioblast Pharma’s Experimental Muscle Wasting Drug Offers Hope

The company said its lead drug in development, Cabaletta, hit the main goal of proving to be safe and tolerable in the study on patient suffering from oculopharyngeal muscular dystrophy.

BioBlast said the drug improved patients' muscle function while also reducing difficulty in swallowing.

Oculopharyngeal muscular dystrophy is a rare disease where patients develop swallowing difficulties, which could lead to death in severe cases.

The company said it would discuss results from this study and a second mid-stage study with the U.S. Food and Drug Administration before it started a late-stage study.



Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Signature Drug Toxicity Dystonia Muscle Atrophy 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive